Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 619

1.

Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly.

Toyama M, Sakakibara N, Takeda M, Okamoto M, Watashi K, Wakita T, Sugiyama M, Mizokami M, Ikeda M, Baba M.

Virus Res. 2019 Jul 31;271:197677. doi: 10.1016/j.virusres.2019.197677. [Epub ahead of print]

PMID:
31376401
2.

Validity of administrative database detection of previously resolved hepatitis B virus in Japan.

Imai S, Yamana H, Inoue N, Akazawa M, Horiguchi H, Fushimi K, Migita K, Yatsuhashi H, Sugiyama M, Mizokami M.

J Med Virol. 2019 Jul 8. doi: 10.1002/jmv.25540. [Epub ahead of print]

PMID:
31283012
3.

Serologic testing of randomly selected children after hepatitis B vaccination: a cross-sectional population-based study in Lao People's Democratic Republic.

Norizuki M, Kitamura T, Komada K, Sugiyama M, Mizokami M, Xeuatvongsa A, Som-Oulay V, Vongphrachanh P, Machida M, Wada K, Ishii K, Kiyohara T, Wakita T, Hachiya M.

BMC Infect Dis. 2019 Jun 10;19(1):507. doi: 10.1186/s12879-019-4086-0.

4.

Optimal titer of anti-HBs in blood components derived from donors with anti-HBc.

Hoshi Y, Hasegawa T, Yamagishi N, Mizokami M, Sugiyama M, Matsubayashi K, Uchida S, Nagai T, Satake M.

Transfusion. 2019 Aug;59(8):2602-2611. doi: 10.1111/trf.15393. Epub 2019 Jun 6.

PMID:
31168835
5.

Effects of bowel preparation on the human gut microbiome and metabolome.

Nagata N, Tohya M, Fukuda S, Suda W, Nishijima S, Takeuchi F, Ohsugi M, Tsujimoto T, Nakamura T, Shimomura A, Yanagisawa N, Hisada Y, Watanabe K, Imbe K, Akiyama J, Mizokami M, Miyoshi-Akiyama T, Uemura N, Hattori M.

Sci Rep. 2019 Mar 11;9(1):4042. doi: 10.1038/s41598-019-40182-9.

6.

Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia.

Younossi ZM, Henry L, P Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim YS, Dan YY, Yu ML, Stepanova M.

Aliment Pharmacol Ther. 2019 Mar;49(6):644-653. doi: 10.1111/apt.15131. Epub 2019 Feb 13. Review.

PMID:
30761562
7.

Association of serum interferon-λ3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents.

Inoue-Shinomiya E, Murakawa M, Asahina Y, Nakagawa M, Tsuchiya J, Sato A, Tsunoda T, Miyoshi M, Nitta S, Kawai-Kitahata F, Itsui Y, Azuma S, Kakinuma S, Murata K, Mizokami M, Watanabe M.

Hepatol Res. 2019 May;49(5):500-511. doi: 10.1111/hepr.13307. Epub 2019 Feb 7.

PMID:
30623518
8.

Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA.

Deng L, Gan X, Ito M, Chen M, Aly HH, Matsui C, Abe T, Watashi K, Wakita T, Suzuki T, Okamoto T, Matsuura Y, Mizokami M, Shoji I, Hotta H.

J Virol. 2019 Mar 5;93(6). pii: e02203-18. doi: 10.1128/JVI.02203-18. Print 2019 Mar 15.

PMID:
30567989
9.

Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo.

Ishida Y, Hayashida T, Sugiyama M, Tsuchiya K, Kikuchi Y, Mizokami M, Oka S, Gatanaga H.

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):350-357. doi: 10.1097/QAI.0000000000001919.

PMID:
30550489
10.

Response to the letter by Dr. Naoya Yamada, and Dr. Koichi Mizuta regarding our manuscript: "Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis".

Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M.

J Gastroenterol. 2019 Feb;54(2):206-207. doi: 10.1007/s00535-018-1524-5. No abstract available.

PMID:
30413874
11.

Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients.

Yoshio S, Mano Y, Doi H, Shoji H, Shimagaki T, Sakamoto Y, Kawai H, Matsuda M, Mori T, Osawa Y, Korenaga M, Sugiyama M, Mizokami M, Mita E, Katayama K, Tanaka J, Kanto T.

JCI Insight. 2018 Oct 18;3(20). pii: 122268. doi: 10.1172/jci.insight.122268.

12.

Association Between High Levels of Hepatitis B Core Antibody and Seroclearance of Hepatitis B e Antigen in Individuals With Chronic Hepatitis B Virus Infection.

Liu J, Hu HH, Chang CL, Jen CL, Lee MH, Lu SN, Wang LY, Yuan Q, Xia NS, Sugiyama M, Nishida N, Mizokami M, Chen CJ, Chen PJ, Yang HI.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1413-1415. doi: 10.1016/j.cgh.2018.09.037. Epub 2018 Sep 26.

PMID:
30267868
13.

A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements.

Lin YJ, Chang CL, Chen LC, Hu HH, Liu J, Korenaga M, Huang YH, Jen CL, Su CY, Nishida N, Sugiyama M, Lu SN, Wang LY, Yuan Y, L'Italien G, Yang HI, Mizokami M, Chen CJ, Lee MH.

Clin Transl Gastroenterol. 2018 Sep 20;9(9):183. doi: 10.1038/s41424-018-0050-3.

14.

HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China.

Wei L, Omata M, Lim YS, Xie Q, Hou JL, Jia J, Hedskog C, Martin R, Doehle B, Yang J, De-Oertel S, Massetto B, Kersey K, Brainard DM, Svarovskaia E, Mo H, Han KH, Mizokami M, Duan Z.

Antiviral Res. 2018 Oct;158:178-184. doi: 10.1016/j.antiviral.2018.08.001. Epub 2018 Aug 16.

PMID:
30120954
15.

Highly Sensitive Glycan Profiling of Hepatitis B Viral Particles and a Simple Method for Dane Particle Enrichment.

Wagatsuma T, Kuno A, Angata K, Tajiri K, Takahashi J, Korenaga M, Mizokami M, Narimatsu H.

Anal Chem. 2018 Sep 4;90(17):10196-10203. doi: 10.1021/acs.analchem.8b01030. Epub 2018 Aug 20.

PMID:
30074767
16.

Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.

Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M.

Hepatol Int. 2018 Jul;12(4):356-367. doi: 10.1007/s12072-018-9878-6. Epub 2018 Jul 20.

17.

Frequency and Characteristics of Occult Hepatitis B Infection Among Hepatocellular Carcinoma Patients in Japan.

Muto J, Sugiyama M, Shirabe K, Mukaide M, Kirikae-Muto I, Ikegami T, Yoshizumi T, Yamashita YI, Maehara Y, Mizokami M.

Ann Hepatol. 2018 July - August ,;17(4):596-603. doi: 10.5604/01.3001.0012.0927.

18.

An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People.

Hayashi S, Khan A, Simons BC, Homan C, Matsui T, Ogawa K, Kawashima K, Murakami S, Takahashi S, Isogawa M, Ikeo K, Mizokami M, McMahon BJ, Tanaka Y.

Hepatology. 2019 Jan;69(1):19-33. doi: 10.1002/hep.30111. Epub 2018 Dec 10.

PMID:
29893492
19.

Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma.

Sawai H, Nishida N, Khor SS, Honda M, Sugiyama M, Baba N, Yamada K, Sawada N, Tsugane S, Koike K, Kondo Y, Yatsuhashi H, Nagaoka S, Taketomi A, Fukai M, Kurosaki M, Izumi N, Kang JH, Murata K, Hino K, Nishina S, Matsumoto A, Tanaka E, Sakamoto N, Ogawa K, Yamamoto K, Tamori A, Yokosuka O, Kanda T, Sakaida I, Itoh Y, Eguchi Y, Oeda S, Mochida S, Yuen MF, Seto WK, Poovorawan Y, Posuwan N, Mizokami M, Tokunaga K.

Sci Rep. 2018 May 21;8(1):7958. doi: 10.1038/s41598-018-26217-7.

20.

De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry.

Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, Ogasawara Y, Tanaka Y, Mizokami M, Sureau C, Suga H, Wakita T.

Cell Chem Biol. 2018 Jul 19;25(7):906-915.e5. doi: 10.1016/j.chembiol.2018.04.011. Epub 2018 May 17.

21.

Hepatitis B virus reactivation in patients with rheumatoid arthritis: Analysis of the National Database of Japan.

Fujita M, Sugiyama M, Sato Y, Nagashima K, Takahashi S, Mizokami M, Hata A.

J Viral Hepat. 2018 Nov;25(11):1312-1320. doi: 10.1111/jvh.12933. Epub 2018 Jun 13.

PMID:
29770539
22.

Phylogenetic and phylodynamic analyses of hepatitis C virus subtype 1a in Okinawa, Japan.

Hoshino K, Sugiyama M, Date T, Maruwaka S, Arakaki S, Shibata D, Maeshiro T, Hokama A, Sakugawa H, Kanto T, Fujita J, Mizokami M.

J Viral Hepat. 2018 Aug;25(8):976-985. doi: 10.1111/jvh.12898. Epub 2018 May 2.

PMID:
29577516
23.

Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine.

Nishida N, Sugiyama M, Sawai H, Nishina S, Sakai A, Ohashi J, Khor SS, Kakisaka K, Tsuchiura T, Hino K, Sumazaki R, Takikawa Y, Murata K, Kanda T, Yokosuka O, Tokunaga K, Mizokami M.

Hepatology. 2018 Mar 13. doi: 10.1002/hep.29876. [Epub ahead of print]

24.

Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.

Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M.

J Viral Hepat. 2018 Aug;25(8):945-951. doi: 10.1111/jvh.12886. Epub 2018 Mar 14.

PMID:
29478258
25.

Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease.

Masugi Y, Abe T, Tsujikawa H, Effendi K, Hashiguchi A, Abe M, Imai Y, Hino K, Hige S, Kawanaka M, Yamada G, Kage M, Korenaga M, Hiasa Y, Mizokami M, Sakamoto M.

Hepatol Commun. 2017 Nov 27;2(1):58-68. doi: 10.1002/hep4.1121. eCollection 2018 Jan.

26.

Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis.

Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, Narimatsu H, Mizokami M.

J Gastroenterol. 2018 Jul;53(7):819-826. doi: 10.1007/s00535-017-1425-z. Epub 2018 Jan 9. Review.

PMID:
29318378
27.

Reduced therapeutic effect of antiviral drugs in patients with hepatitis B virus reactivation after hematopoietic stem cell transplantation.

Kimura M, Nishikawa K, Sakamaki H, Mizokami M, Kimura K.

Hepatol Res. 2018 May;48(6):469-478. doi: 10.1111/hepr.13044. Epub 2018 Jan 10.

PMID:
29235226
28.

Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.

Tamori A, Abiru S, Enomoto H, Kioka K, Korenaga M, Tani J, Enomoto M, Sugiyama M, Masaki T, Kawada N, Yatsuhashi H, Nishiguchi S, Mizokami M.

J Viral Hepat. 2018 May;25(5):608-611. doi: 10.1111/jvh.12840. Epub 2017 Dec 28.

PMID:
29194858
29.

Investigating the hepatitis B virus life cycle using engineered reporter hepatitis B viruses.

Nishitsuji H, Harada K, Ujino S, Zhang J, Kohara M, Sugiyama M, Mizokami M, Shimotohno K.

Cancer Sci. 2018 Jan;109(1):241-249. doi: 10.1111/cas.13440. Epub 2017 Dec 7.

30.

Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients.

Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI.

Sci Rep. 2017 Oct 30;7(1):14352. doi: 10.1038/s41598-017-14747-5.

31.

Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.

Uemura H, Tsukada K, Mizushima D, Aoki T, Watanabe K, Kinai E, Teruya K, Gatanaga H, Kikuchi Y, Sugiyama M, Mizokami M, Oka S.

PLoS One. 2017 Oct 18;12(10):e0186255. doi: 10.1371/journal.pone.0186255. eCollection 2017.

32.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.

33.

Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.

Lee MH, Huang YH, Chen HY, Khor SS, Chang YH, Lin YJ, Jen CL, Lu SN, Yang HI, Nishida N, Sugiyama M, Mizokami M, Yuan Y, L'Italien G, Tokunaga K, Chen CJ; REVEAL-HCV Cohort Study Group.

Hepatology. 2018 Feb;67(2):651-661. doi: 10.1002/hep.29531. Epub 2018 Jan 1.

PMID:
28921602
34.

Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication.

Iwamoto M, Cai D, Sugiyama M, Suzuki R, Aizaki H, Ryo A, Ohtani N, Tanaka Y, Mizokami M, Wakita T, Guo H, Watashi K.

Sci Rep. 2017 Sep 6;7(1):10620. doi: 10.1038/s41598-017-11015-4.

35.

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.

Kimura K, Ikoma A, Shibakawa M, Shimoda S, Harada K, Saio M, Imamura J, Osawa Y, Kimura M, Nishikawa K, Okusaka T, Morita S, Inoue K, Kanto T, Todaka K, Nakanishi Y, Kohara M, Mizokami M.

EBioMedicine. 2017 Sep;23:79-87. doi: 10.1016/j.ebiom.2017.08.016. Epub 2017 Aug 19.

36.

Erratum to: Virological and Clinical Characteristics of Hepatitis B Virus Genotype A.

Ito K, Yoneda M, Sakamoto K, Mizokami M.

J Gastroenterol. 2018 Jan;53(1):163-164. doi: 10.1007/s00535-017-1373-7. No abstract available.

PMID:
28744824
37.

Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9.

Kurihara T, Fukuhara T, Ono C, Yamamoto S, Uemura K, Okamoto T, Sugiyama M, Motooka D, Nakamura S, Ikawa M, Mizokami M, Maehara Y, Matsuura Y.

Sci Rep. 2017 Jul 21;7(1):6122. doi: 10.1038/s41598-017-05905-w.

38.

Virological and Clinical Characteristics of Hepatitis B Virus Genotype A.

Ito K, Yoneda M, Sakamoto K, Mizokami M.

J Gastroenterol. 2018 Jan;53(1):18-26. doi: 10.1007/s00535-017-1367-5. Epub 2017 Jul 7. Review. Erratum in: J Gastroenterol. 2017 Jul 25;:.

PMID:
28687901
39.

Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.

Shoji H, Yoshio S, Mano Y, Doi H, Sugiyama M, Osawa Y, Kimura K, Arai T, Itokawa N, Atsukawa M, Aoki Y, Fukai M, Taketomi A, Mizokami M, Kanto T.

Int J Cancer. 2017 Sep 1;141(5):1011-1017. doi: 10.1002/ijc.30804. Epub 2017 Jun 8.

40.

Development of an assay system for large scale analysis of HLA class II-binding peptides.

Miyadera H, Noguchi E, Mizokami M, Tokunaga K.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):35-39. doi: 10.2177/jsci.40.35. Review. Japanese.

41.

A human PSMB11 variant affects thymoproteasome processing and CD8+ T cell production.

Ohigashi I, Ohte Y, Setoh K, Nakase H, Maekawa A, Kiyonari H, Hamazaki Y, Sekai M, Sudo T, Tabara Y, Sawai H, Omae Y, Yuliwulandari R, Tanaka Y, Mizokami M, Inoue H, Kasahara M, Minato N, Tokunaga K, Tanaka K, Matsuda F, Murata S, Takahama Y.

JCI Insight. 2017 May 18;2(10). pii: 93664. doi: 10.1172/jci.insight.93664. eCollection 2017 May 18.

42.

Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma.

Tamaki N, Kuno A, Matsuda A, Tsujikawa H, Yamazaki K, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Korenaga M, Mizokami M, Kurosaki M, Sakamoto M, Narimatsu H, Izumi N.

Sci Rep. 2017 Mar 21;7(1):244. doi: 10.1038/s41598-017-00357-8.

43.

Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population.

Trinks J, Nishida N, Hulaniuk ML, Caputo M, Tsuchiura T, Marciano S, Haddad L, Blejer J, Bartoli S, Ameigeiras B, Frías SE, Vistarini C, Heinrich F, Remondegui C, Ceballos S, Echenique G, Charre Samman M, D'Amico C, Rojas A, Martínez A, Ridruejo E, Fernández RJ, Burgos Pratx L, Salamone H, Nuñez F, Galdame O, Gadano A, Corach D, Sugiyama M, Flichman D, Tokunaga K, Mizokami M.

Liver Int. 2017 Oct;37(10):1476-1487. doi: 10.1111/liv.13405. Epub 2017 Mar 30.

PMID:
28267888
44.

Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials.

Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S.

Health Qual Life Outcomes. 2017 Jan 31;15(1):25. doi: 10.1186/s12955-017-0598-8.

45.

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M.

J Hepatol. 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. Epub 2017 Jan 18.

PMID:
28108232
46.

Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection.

Nagao Y, Nishida N, Toyo-Oka L, Kawaguchi A, Amoroso A, Carrozzo M, Sata M, Mizokami M, Tokunaga K, Tanaka Y.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):937-944.e5. doi: 10.1016/j.cgh.2016.12.029. Epub 2017 Jan 5.

47.

Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population.

Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, Nakamura H, Tanaka A, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Abe M, Nakao K, Yamagiwa S, Kaneko S, Honda M, Umemura T, Ichida T, Seike M, Sakisaka S, Harada M, Yokosuka O, Ueno Y, Senju M, Kanda T, Shibata H, Himoto T, Murata K, Miyake Y, Ebinuma H, Taniai M, Joshita S, Nikami T, Ota H, Kouno H, Kouno H, Nakamuta M, Fukushima N, Kohjima M, Komatsu T, Komeda T, Ohara Y, Muro T, Yamashita T, Yoshizawa K, Nakamura Y, Shimada M, Hirashima N, Sugi K, Ario K, Takesaki E, Naganuma A, Mano H, Yamashita H, Matsushita K, Yamauchi K, Makita F, Nishimura H, Furuta K, Takahashi N, Kikuchi M, Masaki N, Tanaka T, Tamura S, Mori A, Yagi S, Shirabe K, Komori A, Migita K, Ito M, Nagaoka S, Abiru S, Yatsuhashi H, Yasunami M, Shimoda S, Harada K, Egawa H, Maehara Y, Uemoto S, Kokudo N, Takikawa H, Ishibashi H, Chayama K, Mizokami M, Nagasaki M, Tokunaga K, Nakamura M.

Hum Mol Genet. 2017 Feb 1;26(3):650-659. doi: 10.1093/hmg/ddw406.

PMID:
28062665
48.

Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.

Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T.

J Hepatol. 2017 Apr;66(4):685-692. doi: 10.1016/j.jhep.2016.11.009. Epub 2016 Nov 25.

PMID:
27890789
49.

A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.

Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, Aizaki H, Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T.

Hepatology. 2017 Apr;65(4):1104-1116. doi: 10.1002/hep.28952. Epub 2017 Jan 17.

PMID:
27863453
50.

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.

Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M.

Gut. 2018 Feb;67(2):362-371. doi: 10.1136/gutjnl-2016-312653. Epub 2016 Oct 27.

Supplemental Content

Loading ...
Support Center